An investigational, first-in-class antipsychotic is showing promise as an effective agent in the treatment of schizophrenia, with an improved side effect profile, results from a phase 2 study suggest.
ITI-007 ([Intra-Cellular Therapies Inc), a unique, multitasking antipsychotic, was effective and demonstrated reduced motor and metabolic side effects compared with the antipsychotic risperidone (Risperdal, Janssen Pharmaceuticals, Inc).
“This drug has a different pharmacological profile than any of the other antipsychotics,” said Kimberly E. Vanover, PhD, an employee of Intra-Cellular Therapies.
…
The results so far suggest that the drug could indeed offer a new option for schizophrenia treatment, Charles Schulz, MD, professor and head of the Department of Psychiatry at the University of Minnesota, in Minneapolis, told Medscape Medical News.
“The trial came across as a potentially important addition to the treatment of schizophrenia, and the activity was described as somewhat similar to clozapine, which is effective without too much dopamine blockade,” said Dr Schulz, who moderated the session.
“The weight issues were well described and useful as well, which is an important health area.”
Read the full story here: